{"id":"NCT02727751","sponsor":"Ardelyx","briefTitle":"A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C","officialTitle":"An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2017-10","completion":"2017-10","firstPosted":"2016-04-05","resultsPosted":"2020-04-24","lastUpdate":"2020-09-09"},"enrollment":312,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Constipation Predominant Irritable Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"Tenapanor","otherNames":["RDX5791","AZD1722"]}],"arms":[{"label":"50mg BID","type":"EXPERIMENTAL"}],"summary":"This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.","primaryOutcome":{"measure":"Adverse Events in >2% Patients","timeFrame":"52-55 weeks","effectByArm":[{"arm":"50mg BID","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33337659"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":312},"commonTop":["Diarrhea"]}}